HEPARIN SODIUM; TAUROLIDINE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for heparin sodium; taurolidine and what is the scope of patent protection?

Heparin sodium; taurolidine is the generic ingredient in one branded drug marketed by Cormedix and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Heparin sodium; taurolidine has fourteen patent family members in eight countries.

One supplier is listed for this compound.

Summary for HEPARIN SODIUM; TAUROLIDINE

International Patents:	14
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	HEPARIN SODIUM; TAUROLIDINE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HEPARIN SODIUM; TAUROLIDINE

Generic Entry Date for HEPARIN SODIUM; TAUROLIDINE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: GENERATING ANTIBIOTIC INCENTIVES NOW Dosage: SOLUTION;N/A

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for HEPARIN SODIUM; TAUROLIDINE

Drug Class	Anti-coagulant Unfractionated Heparin

Anatomical Therapeutic Chemical (ATC) Classes for HEPARIN SODIUM; TAUROLIDINE

US Patents and Regulatory Information for HEPARIN SODIUM; TAUROLIDINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for HEPARIN SODIUM; TAUROLIDINE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023	⤷ Sign Up	⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023	⤷ Sign Up	⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023	⤷ Sign Up	⤷ Sign Up
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for HEPARIN SODIUM; TAUROLIDINE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006049813		⤷ Sign Up
Portugal	1814562		⤷ Sign Up
China	101094679	Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin	⤷ Sign Up
Denmark	1814562		⤷ Sign Up
China	103083353	Antimicrobial Locking Solutions Comprising Taurinamide Derivatives And Biologically Acceptable Salts And Acids, With The Addition Of Small Concentrations Of Heparin	⤷ Sign Up
European Patent Office	1814562	SOLUTIONS DE BLOCAGE ANTI-MICROBIEN COMPRENANT DES DERIVES DE TAURINAMIDE AINSI QUE DES SELS ET DES ACIDES BIOLOGIQUEMENT ACCEPTABLES, AVEC ADJONCTION D'HEPARINE EN FAIBLES CONCENTRATIONS (ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for HEPARIN SODIUM; TAUROLIDINE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for HEPARIN SODIUM; TAUROLIDINE

Pharmacology for HEPARIN SODIUM; TAUROLIDINE

Anatomical Therapeutic Chemical (ATC) Classes for HEPARIN SODIUM; TAUROLIDINE

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HEPARIN SODIUM; TAUROLIDINE